Digital Maternity care needs improvement, healthtech can help The Birth Trauma Inquiry collected evidence from 1,300 women and found that maternity care of “
News NICE backs first targeted therapy for ALK+ lung cancer Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.